Literature DB >> 25614173

Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis.

Antoni Torres1, Catia Cillóniz2, Miquel Ferrer2, Albert Gabarrús2, Eva Polverino2, Santiago Villegas3, Francesc Marco4, Josep Mensa5, Rosario Menéndez6, Michael Niederman7.   

Abstract

The sensitivity of blood cultures in the diagnosis of bacteraemia for community-acquired pneumonia is low. Recommendations, by guidelines, to perform blood cultures are discordant. We aimed to determine the incidence, microbial aetiology, risk factors and outcomes of bacteraemic patients with community-acquired pneumonia, including cases with antibiotic-resistant pathogens (ARP). A prospective, observational study was undertaken on consecutive adult patients admitted to the Hospital Clinic of Barcelona (Barcelona, Spain) with community-acquired pneumonia and blood cultures were obtained. Of the 2892 patients included, bacteraemia was present in 297 (10%) patients; 30 (10%) of whom had ARP (multidrug-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, and an extended spectrum of beta-lactamase producing Enterobacteriaceae). In multivariate analyses, pleuritic pain, C-reactive protein ≥21.6 mg·dL(-1) and intensive care unit admissions were independently associated with bacteraemia, while prior antibiotic treatment and pneumococcal vaccine were protective factors. The risk factors for ARP bacteraemia were previous antibiotics and C-reactive protein <22.2 mg·dL(-1), while pleuritic pain was the only protective factor in the multivariate analysis. Bacteraemia (excluding ARP), appropriate empiric treatment, neurological disease, arterial oxygen tension/inspiratory oxygen fraction <250, pneumonia severity index risk classes IV and V, and intensive care unit admission were independently associated with a 30-day hospital mortality in the multivariate analysis. Inappropriate therapy was more frequent in ARP bacteraemia, compared with other bacteraemias (27% versus 3%, respectively, p<0.001). Antibiotic therapy protected against bacteraemia, but increased specifically the risk of bacteraemia from ARP due to the inappropriate coverage of these pathogens. Identifying patients at risk of ARP bacteraemia would help in deciding appropriate empiric antimicrobial therapy. The results from this study provide evidence concerning community-acquired pneumonia patients in whom blood cultures should not be performed.
Copyright ©ERS 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25614173     DOI: 10.1183/09031936.00152514

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  14 in total

1.  Anti-PD-L1 Therapy Does Not Improve Survival in a Murine Model of Lethal Staphylococcus aureus Pneumonia.

Authors:  Colleen S Curran; Lindsay M Busch; Yan Li; Cui Xizhong; Junfeng Sun; Peter Q Eichacker; Parizad Torabi-Parizi
Journal:  J Infect Dis       Date:  2021-12-15       Impact factor: 5.226

2.  Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis.

Authors:  Adoración Navarro-Torné; Eva Agostina Montuori; Vasiliki Kossyvaki; Cristina Méndez
Journal:  Hum Vaccin Immunother       Date:  2021-06-09       Impact factor: 4.526

3.  Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England.

Authors:  Albert Jan van Hoek; Elizabeth Miller
Journal:  PLoS One       Date:  2016-02-25       Impact factor: 3.240

4.  Predictive factors of true bacteremia and the clinical utility of blood cultures as a prognostic tool in patients with community-onset pneumonia.

Authors:  Jong Hoo Lee; Yee Hyung Kim
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

Review 5.  Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns.

Authors:  Catia Cilloniz; Ignacio Martin-Loeches; Carolina Garcia-Vidal; Alicia San Jose; Antoni Torres
Journal:  Int J Mol Sci       Date:  2016-12-16       Impact factor: 5.923

6.  Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of a prospective observational cohort.

Authors:  Akihiro Ito; Tadashi Ishida; Hironobu Tokumasu; Yasuyoshi Washio; Akio Yamazaki; Yuhei Ito; Hiromasa Tachibana
Journal:  BMC Pulm Med       Date:  2017-05-02       Impact factor: 3.317

7.  The Antibacterial and Anti-inflammatory Activity of Chicken Cathelicidin-2 combined with Exogenous Surfactant for the Treatment of Cystic Fibrosis-Associated Pathogens.

Authors:  Brandon J H Banaschewski; Brandon Baer; Christina Arsenault; Teah Jazey; Edwin J A Veldhuizen; Johan Delport; Tracey Gooyers; James F Lewis; Henk P Haagsman; Ruud A W Veldhuizen; Cory Yamashita
Journal:  Sci Rep       Date:  2017-11-14       Impact factor: 4.379

8.  Mechanisms of antimicrobial resistance in Gram-negative bacilli.

Authors:  Étienne Ruppé; Paul-Louis Woerther; François Barbier
Journal:  Ann Intensive Care       Date:  2015-08-12       Impact factor: 6.925

9.  Effects of age, comorbidity and adherence to current antimicrobial guidelines on mortality in hospitalized elderly patients with community-acquired pneumonia.

Authors:  Xiudi Han; Fei Zhou; Hui Li; Xiqian Xing; Liang Chen; Yimin Wang; Chunxiao Zhang; Xuedong Liu; Lijun Suo; Jinxiang Wang; Guohua Yu; Guangqiang Wang; Xuexin Yao; Hongxia Yu; Lei Wang; Meng Liu; Chunxue Xue; Bo Liu; Xiaoli Zhu; Yanli Li; Ying Xiao; Xiaojing Cui; Lijuan Li; Jay E Purdy; Bin Cao
Journal:  BMC Infect Dis       Date:  2018-04-24       Impact factor: 3.090

Review 10.  Challenges in severe community-acquired pneumonia: a point-of-view review.

Authors:  Antoni Torres; James D Chalmers; Charles S Dela Cruz; Cristina Dominedò; Marin Kollef; Ignacio Martin-Loeches; Michael Niederman; Richard G Wunderink
Journal:  Intensive Care Med       Date:  2019-01-31       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.